Yake Biotechnology Ltd.
Yake Biotechnology Ltd.
Explore linked clinical trials.30 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma | Large B-Cell Lymphoma (LBCL) | Recruiting | Phase 2 | 2026-04-07 | NCT04661020 | |
| Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-27 | NCT07370064 | |
| A Multicenter Study of CAR-T Cells in Primary Ph+All | acute lymphoblastic leukemia | Recruiting | Phase 2 | 2025-12-04 | NCT07252336 | |
| Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Early phase 1 | 2025-08-27 | NCT07144020 | |
| CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases | Hemic and Lymphatic Diseases, hematologic disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-08-13 | NCT05827835 | |
| Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, desmoplastic small round cell tumor, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor, sarcoma | Recruiting | Phase 1 / Phase 2 | 2025-02-26 | NCT06836505 | |
| Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Early phase 1 | 2025-01-27 | NCT06793241 | |
| CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder | Recruiting | Early phase 1 | 2025-01-22 | NCT06787560 | |
| CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Early phase 1 | 2025-01-21 | NCT06785519 | |
| Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD | Schimke immuno-osseous dysplasia | Recruiting | Early phase 1 | 2025-01-20 | NCT06769191 | |
| A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Early phase 1 | 2025-01-07 | NCT06762132 | |
| A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Early phase 1 | 2024-12-20 | NCT06684639 | |
| Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Early phase 1 | 2024-10-09 | NCT06633354 | |
| Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-lymphoblastic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Early phase 1 | 2024-10-09 | NCT06633341 | |
| CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Recruiting | Early phase 1 | 2024-10-09 | NCT06633328 | |
| CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell | Recruiting | Early phase 1 | 2024-05-14 | NCT06346912 | |
| CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases | autoimmune disease, immune system disorder | Recruiting | Early phase 1 | 2024-04-09 | NCT06279923 | |
| Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2023-11-15 | NCT06132711 | |
| A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2023-10-16 | NCT06084962 | |
| APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2022-05-09 | NCT04657861 | |
| CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2021-11-04 | NCT04662294 | |
| A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Early phase 1 | 2020-12-17 | NCT04670055 | |
| A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Early phase 1 | 2020-12-10 | NCT04541368 | |
| NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Early phase 1 | 2020-12-08 | NCT04658004 | |
| LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies | Disease Attributes, Hemic and Lymphatic Diseases, Infections, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, hematopoietic and lymphoid system neoplasm, infectious disease, neoplasm | Not yet recruiting | Early phase 1 | 2020-12-08 | NCT04657965 |